Galectin Therapeutics

Galectin Therapeutics

Galectin Therapeutics was founded in 2001 around the therapeutic potential of galectin-3, a protein implicated in fibrosis, cancer, and immune dysregulation. The company pivoted from early oncology ambitions to focus exclusively on liver disease under former CEO Peter Traber, settling into its current identity as a single-asset NASH (nonalcoholic steatohepatitis) drug developer. CEO Joel Lewis, who took the top role in 2021 after serving as Chief Financial Officer, now leads a lean team of approximately 10 professionals operating from Norcross, Georgia — a deliberate overhead-minimizing structure for a microcap biotech with no marketed products. The entire strategy hinges on belapectin (formerly GR-MD-02), an intravenous galectin-3 inhibitor in Phase 3 development for NASH cirrhosis with portal hypertension. The company's NAVIGATE trial, launched in 2022, enrolled over 350 patients across sites in the United States, Canada, Australia, and Israel — an international clinical footprint unusual for a firm of Galectin's size. Belapectin targets the reduction of hepatic venous pressure gradient (HVPG), a hard endpoint that distinguishes it from NASH fibrosis programs at Madrigal Pharmaceuticals and Intercept Pharmaceuticals, which pursued biopsy-based histological endpoints. Galectin has no fund commitments, co-investment vehicles, or balance-sheet allocations beyond its own clinical program. Galectin operated with approximately $15.5 million in cash and equivalents as of December 2023 (per SEC filings), supplemented by an at-the-market equity facility to fund the NAVIGATE trial through data readout. The firm maintains no additional offices, philanthropic foundations, or affiliated investment vehicles — it is a pure-play public biotechnology company trading on NASDAQ under the ticker GALT. In October 2023, the company announced the completion of enrollment for the NAVIGATE adaptive Phase 2b/3 trial, with topline data expected in the second half of 2024. Galectin's structural differentiator is its extreme clinical concentration risk paired with a mechanism that diverges from the field. Unlike metabolic-targeting NASH programs that failed on liver biopsy histology endpoints in companies like Genfit or Gilead, belapectin targets galectin-3 mediated fibrosis and portal hypertension directly — a pathway that could serve the 2-5 million Americans with NASH cirrhosis, a population for which no FDA-approved therapy exists. The firm's entire future depends on one trial readout in one indication, creating an unusually stark binary outcome for a publicly traded entity.